V8 Peptides — Engineered Performance
Research Library
Selank and Semax Stack Research: Combination Design
SelankStacks

Selank and Semax Stack Research: Combination Design

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How is a Selank plus Semax "stack" studied properly in the lab? As a two-factor experiment: vehicle, Selank alone, Semax alone and the combination, run in parallel with identical routes, schedules and readouts. Published work gives reasons to expect overlap, since both heptapeptides inhibited enkephalin-degrading enzymes in the same serum assay and both end in Pro-Gly-Pro, and reasons to expect divergence, since Semax is an ACTH-fragment analog studied for BDNF and trkB expression while Selank is a tuftsin analog studied for GABA-related readouts. No published abstract cited here tests the pair together, so a combination claim needs its own data. Both peptides are supplied by V8 Peptides as separate lyophilized vials, for laboratory research use only.

"Nootropic stack" is a marketing phrase. In a laboratory it becomes a design problem: if two compounds are present together, how can an experiment tell whether the result is the sum of the parts, less than the sum, or something new? This article lays out that design for Selank and Semax, using the published single-compound findings to choose readouts and to anticipate where interference is likely. It describes experimental structure only and makes no claim about effects of the pair. Product facts come from the Selank and Semax product pages; the wider background is in the Selank research guide and the Semax research guide. For laboratory research use only.

Two heptapeptides that share a tail

Both molecules are seven residues long and end in Pro-Gly-Pro. They differ in the first four residues, and that difference is the source of their different research stories.

FeatureSelankSemax
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProMet-Glu-His-Phe-Pro-Gly-Pro
Parent fragmentTuftsin (Thr-Lys-Pro-Arg)ACTH(4-7) region
FormulaC33H57N11O9C37H51N9O10S
Vial size listed10 mg15 mg
Purity specification≥98% HPLC≥98% HPLC
Oxidation-prone residuesNo Met, Cys or TrpMet (sulfur in the formula)
Storage per product page2–8 °C; −20 °C long-term2–8 °C; −20 °C long-term

Because Semax contains methionine, its solutions need more attention to oxygen, light and storage time than Selank's. That is a handling difference to document when both are used in one experiment.

What the single-compound literature suggests

For Semax, a rat hippocampal study reported that a single application at 50 µg/kg produced a maximal 1.4-fold increase in BDNF protein with a 1.6-fold increase in trkB tyrosine phosphorylation and higher exon III BDNF and trkB mRNA levels (reference 1). In a rat cerebral-ischemia model, both Semax and its Pro-Gly-Pro tripeptide activated transcription of neurotrophins and their receptors in cortex, with partly overlapping profiles (reference 2). For Selank, frontal-cortex gene-expression profiling reported changes in many neurotransmission genes (reference 5), and a mouse comparison found anxiolytic- and nootropic-like effects limited to the BALB/c strain, by both intranasal and intraperitoneal routes (reference 6).

The overlap that matters most for a combination is enzymatic. In a human-serum assay, Semax (IC50 10 µM) and Selank (IC50 20 µM) both inhibited enkephalin-degrading enzymes, and pentapeptide fragments of each were also active (reference 3). A separate Selank report gave an IC50 of 15 µM against plasma enkephalin hydrolysis (reference 4). Two inhibitors acting on the same enzymes in the same preparation are expected to compete for the same sites, so a combination in that assay would not be expected to be simply additive. That prediction is a design hypothesis, not a published finding.

The 2 × 2 factorial design

The standard structure for asking whether two factors interact is a factorial layout.

GroupSelankSemaxPurpose
ANo (vehicle)No (vehicle)Baseline for every readout
BYesNo (vehicle)Effect of Selank alone
CNo (vehicle)YesEffect of Semax alone
DYesYesCombined effect

The interaction is read from the four group means: interaction = (D − C) − (B − A). A value near zero is consistent with additivity on the scale measured; a positive or negative value points to synergy or antagonism on that scale. Three details keep this honest. First, every group must receive the same total volume and the same number of administrations, so groups B and C receive a vehicle where the other peptide would be. Second, the scale matters: an additive effect on a raw reading may not be additive on a log scale, so choose the scale before looking at data. Third, the sample size needed to detect an interaction is larger than for a main effect, because the contrast involves four means. Pilot variance is therefore more important here than for a single-compound study.

Add a fifth group if the readout is enzymatic: a mixture with each peptide at half its single-compound concentration is a standard way to test whether two inhibitors of the same enzymes behave additively (the sum of fractional concentrations equals one).

Choosing readouts that distinguish the two

Pick at least one readout per peptide's own literature, then one shared readout.

  • Semax-linked: hippocampal or cortical BDNF protein and mRNA, trkB phosphorylation, with timing drawn from the published one-time-point studies (reference 1).
  • Selank-linked: a targeted panel of GABAergic and neurotransmission genes at one and three hours (reference 5), or hippocampal slice inhibitory currents.
  • Shared: enkephalin-degradation rate in serum or plasma, which both peptides inhibit in vitro (references 3 and 4).
  • Behavior: a plus-maze or open-field readout with a pre-specified primary outcome, in a strain chosen for its baseline (reference 6, with the rationale for strain selection in reference 9).

Using readouts from both literatures prevents a common bias: finding an "effect" only on the measure that one of the peptides was already known to move.

Preparing the vials without cross-contamination

The practical failure points are mixing errors and stability mismatches. Keep separate stocks for each peptide and prepare them in the same session with the same diluent lot, so that diluent is not a confounder. Mixing the two in one vial is rarely necessary; if a combination is applied together, prepare the mix fresh from the two stocks and label it with both concentrations. Because Semax has a methionine, limit its time in solution and avoid unnecessary light and air; general degradation pathways, including oxidation, are reviewed in the pharmaceutical literature (references 7 and 8).

The arithmetic for each stock is the same formula: concentration (mg/mL) = vial mass (mg) ÷ diluent volume (mL), and a mixture's final concentration of each peptide is C_stock × V_stock ÷ V_total. The reconstitution calculator handles unit conversions, and how to reconstitute a lyophilized peptide and how to mix peptides with bacteriostatic water cover technique. Peptide blends sold as fixed mixtures raise their own questions about ratio and stability; those are discussed in peptide blends and research stacks.

Analytical checks before a combination experiment

A combination study multiplies the places an error can hide. Before the first animal or assay plate, confirm each material on paper: lot number, formula, sequence and HPLC purity figure from the COA page where a certificate is published, and the receiving record. The purity percentage is chromatographic; peptide content is lower because counterions and water also occupy the mass, which matters when two peptides are matched by mass. Understanding HPLC purity explains the distinction.

Run a simple stability check as well: an aliquot of the mixed working solution held for the duration of the experiment and compared by HPLC against a fresh one tells whether either peptide changed in the mixture. If the Semax peak decreases or a new peak appears, interpret any combination effect with that in mind.

Interpreting and reporting a result

Report the four-group means with variability, the interaction contrast with its interval, and the preregistered primary outcome. Describe the result by readout, for example "the combination did not differ from the sum of the single-peptide groups in hippocampal BDNF mRNA at two hours", and avoid the word synergy unless a formal test supports it. State plainly that the single-peptide findings come from separate studies with different strains, routes and amounts. The sister article Selank versus Semax compares the two peptides individually, and the shop lists all research vials. Everything here is for laboratory research use only.

Frequently asked questions

Is there published research on Selank and Semax together?

The abstracts cited here describe each peptide separately, plus one human-serum enzyme assay in which both inhibited enkephalin-degrading enzymes. No abstract tests the combination, so a combined claim needs its own experiment.

What is a factorial design?

An experiment with every combination of two factors: vehicle, Selank alone, Semax alone and both. The interaction is (combined − Semax alone) − (Selank alone − vehicle).

Why might the two not be additive?

Both inhibited the same class of enzymes in one serum assay, so competition for the same sites would reduce the combined effect below the sum. This is a design hypothesis to test, not a finding.

What do Selank and Semax have in common?

Both are seven-residue peptides with a C-terminal Pro-Gly-Pro tail. Selank derives from tuftsin and Semax from an ACTH fragment.

Which readouts best separate them?

Hippocampal BDNF and trkB readouts for Semax, GABAergic gene panels or slice currents for Selank, and enkephalin-degradation rate as the shared readout.

Is Semax more fragile in solution?

Semax contains methionine, which can oxidize, while Selank has no Met, Cys or Trp. Limit Semax time in solution and protect it from light and air.

Should the two peptides be mixed in one vial?

Usually no. Keep separate stocks and combine fresh if needed, labeled with both concentrations. Fixed blends raise ratio and stability questions of their own.

How is a mixture's final concentration calculated?

For each peptide: stock concentration times stock volume divided by total final volume. The site's calculator handles the unit conversions.

What storage do the product pages state?

Both list refrigeration at 2–8 °C, −20 °C for long-term holding, and protection from heat, moisture and light.

Is this article a recommendation to combine peptides?

No. It describes how a laboratory could test an interaction. Both materials are for laboratory research use only.

Related reading: Selank vs Semax: Readout-by-Readout Research Ledger, Selank Storage and Stability: A Sequence-Based View, How Selank Is Made: Synthesis Steps and Impurities.

References

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108
  2. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-9. doi:10.1007/s10571-009-9432-0
  3. Kost NV, Sokolov OIu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, et al. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorg Khim. 2001;27(3):180-3. PMID: 11443939
  4. Zozulya AA, Kost NV, Yu Sokolov O, Gabaeva MV, Grivennikov IA, Andreeva LN, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-7. doi:10.1023/a:1017979514274
  5. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. doi:10.3389/fphar.2016.00031
  6. Vasil'eva EV, Kondrakhin EA, Salimov RM, Kovalev GI. [COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.]. Eksp Klin Farmakol. 2016;79(9):3-11. PMID: 29787664
  7. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75. doi:10.1007/s11095-009-0045-6
  8. Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
  9. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14(3):149-67. doi:10.1016/0165-0270(85)90031-7

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.